What is the main business of Direct Pharma Polska?

The main business activity of Direct Pharma Polska focuses on manufacture of pharmaceutical preparations.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on March 7, 2018.

Where is the headquarters located?

The headquarters is located at: ul. Zygmunta Radnickiego 11, 30-498 Kraków.

What is the share capital?

The share capital of the company is PLN 7,950 (approx. $2,147).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2023 to December 31, 2023.

What was the revenue?

The company reported a revenue of $61,017 in 2023, which is a decrease of 40.3% compared to 2022.

No, in 2023 the company was not profitable, reporting a net loss of $33,116. For comparison, in 2022 the loss was $18,542, meaning the company increased its loss by 68.3%.

Direct Pharma Polskasp. z o.o.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2018-03-07

Share capital

7,950.00 PLN

Registered address

ul. Zygmunta Radnickiego 11, 30-498 Kraków, Poland

Financials

Revenue history (in k)

Filing timeliness

No financial statement for 2024 – the filing deadline has passed. 5 of 6 financial statements were filed late (the longest delay 1808 days for 2018).

2024not filed
202327/06/2024
202226/06/2024
202126/06/2024
202026/06/2024
201926/06/2024

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Sanctions and PEP lists

Person	List	Match
Bogdan Leszek Podgórski	Poseł do Parlamentu Europejskiego	confirmed

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2023.

Results vs industry

Revenue

This companyUSD 61.02kMedianUSD 919.05kAverageUSD 25.83m

Net profit

This companyUSD -33.12kMedianUSD 14.92kAverageUSD 2.77m

Operating costs

This companyUSD 94.03kMedianUSD 873.06kAverageUSD 21.43m

Assets

This companyUSD 401.62kMedianUSD 897.46kAverageUSD 31.52m

Industry

Authorized Representatives

Joanna Iwona Maleszka – President of the Management Board

Manner of representation

The company may be represented by the President of the Management Board independently, while the other members of the management board only jointly with the President of the Management Board.

Ownership

Owner	Shares	Share value	Stake
Joanna Iwona Maleszkaage 56	95	$1,283.09	59.7484%
Gabriel Michał Mitraszewskiage 76	32	$432.20	20.1258%
Bogdan Leszek Podgórskiage 76	32	$432.20	20.1258%

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2018-04-27.

No bank accounts reported to the VAT Taxpayer Register.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

Grant date	Purpose	Gross amount	Granting body
Apr 29, 2020	De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)	$626$626	Prezes Banku Gospodarstwa Krajowego
Apr 26, 2019	De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)	$156$156	Prezes Banku Gospodarstwa Krajowego

Competitors

Name	Revenue	Website
Instytut Biotechnologii Surowic i Szczepionek Biomed - Skrót Firmy Ibss BiomedS.A.	$37,103,878.54	biomed.pl
Fagronsp. z o.o.	$21,715,187.73	fagron.pl
Krakowskie Zakłady Zielarskie Herbapol w KrakowieS.A.	$7,294,338.51	herbapol.krakow.pl
F1 PharmaS.A.	$272,113.66	f1pharma.pl
LideoS.A.	$95,067.91	lideo.tech
Munar PharmaS.A.	$85,649.72	munar.pl
BIO Animalisp. z o.o.	$49,176.96	proanimali.com
Ampliconsp. z o.o.	$48,330.99	amplicon.pl
Xenira Pharmaceuticalssp. z o.o.	$26,670.82	xenirapharma.com
Zakład Farmaceutyczny Amarasp. j.	$0.00	amara.pl